onartuzumab   Click here for help

GtoPdb Ligand ID: 8966

Synonyms: MetMAb | OA-5D5 | OA5D5 | PRO 143966
Compound class: Antibody
Comment: Onartuzumab is an investigational, humanized monoclonal antibody targeting the MET receptor tyrosine kinase, a proto-oncogene which acts as a hepatocyte growth factor receptor. The protein is a monovalent (single-armed) construct, as opposed to bi-valent intact antibody structures.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record.
BLAST peptide analysis reveals identical match with sequences deposited with patent US7615529 [4], which relate to the monoclonal isolated from hybridoma 5D5.11.6 therein.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
In early 2014, a Phase 3 study of onartuzumab (in combination with erlotinib; NCT01456325) in patients with MET-positive non-small cell lung cancer was terminated due to a lack of clinically meaningful efficacy [1,7]. Additional Phase 3 studies evaluating onartuzumab's antineoplastic activity in MET-positive lung, gastric and other solid cancers are ongoing [6]. Click here to link to ClinicalTrials.gov's list of Phase 3 onartuzumab trials.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
MET proteins dimerise upon hepatocyte growth factor (HGF) binding. This triggers a signalling cascade that promotes cell growth, division and migration. Activation of the MET pathway has been proposed as a mechanism of tumour growth and metastasis [3,5].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01456325 A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung) Phase 3 Interventional Genentech, Inc.